The IR Evolution in Oncology: Tools, Treatments, and Guidelines

Area of Science:

• Interventional oncology
• Oncologic treatments
• Clinical outcomes research

Background:

• Historically, interventional oncology focused on technical skills and imaging guidance rather than patient outcomes.
• A competitive "red ocean" market strategy against surgery has hindered adoption and trial success.
• Challenges exist in demonstrating overall survival benefits in randomized trials due to subsequent therapies.

Purpose of the Study:

• To advocate for interventional oncology to transition from "procedures" to "treatments" with a focus on clinical outcomes.
• To propose a "blue ocean" strategy, targeting unmet needs where interventional oncology offers unique, less invasive solutions.
• To emphasize the need for interventional oncologists to actively shape the field's future through research, guidelines, and public dissemination.

Main Methods:

• Analysis of the current market positioning and strategic challenges of interventional oncology.
• Review of the need for clinical continuity of care, including multidisciplinary team involvement and patient follow-up.
• Examination of recent guideline inclusions (e.g., ESMO for colorectal cancer) and their implications.

Main Results:

• Interventional oncology is increasingly recognized, with thermal ablation now categorized alongside surgical resection for specific indications.
• The field faces challenges in trial design, particularly with overall survival as an endpoint.
• A strategic shift towards "blue ocean" opportunities is proposed to leverage interventional oncology's disruptive potential.

Conclusions:

• Interventional oncologists must prioritize clinically relevant outcomes and comprehensive patient care.
• Adopting a "blue ocean" strategy can unlock new markets and demonstrate unique value.
• Proactive engagement in research, scientific societies, and public communication is essential for establishing interventional oncology as a disruptive and indispensable treatment modality.